Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
14 results
D3.166 - Attention-deficit/hyperactivity disorder (ADHD) in asthmatic children
D3.168 - Clinical Department of Allergy Center in Linköping
D3.169 - Paediatric Severe Acute Respiratory Infections in Malta: A Three-Year Review
D3.171 - Validation of the Kazakh Version of the Asthma Quality of Life Questionnaire (AQLQ) for Clinical Use in Adult Patients with Asthma
D3.173 - Switching from Dupilumab to Tezepelumab in a Child with Severe Asthma and Atopic Dermatitis: Clinical Considerations and Therapeutic Implications
D3.174 - Short-term tolerance of omlyclo, the omalizumab biosimilar
D3.175 - Algorithm for Biologics Selection in Severe Asthma
D3.178 - Assessment of blood rheological properties in children with bronchial asthma
D3.179 - Longitudinal breath profiling of exhaled volatile organic compounds differentiates viral-induced asthma exacerbation from clinical control
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
Download the app
The congress at your fingertips
Available on
Download